Castle Biosciences
CareDx, Castle Bio, Lucira Health, Others Announce Preliminary Q4, FY21 Earnings Results
CareDx's Q4 revenues rose between 34 percent and 35 percent, while OpGen Q4 revenues were flat compared to the previous year.
360Dx Index Follows Larger Market Trends, Drops 4 Percent in November
Of the 29 companies in the index, 10 saw increases in their stock prices, while 19 saw declines.
Castle Biosciences Q3 Revenues Rise 54 Percent
The company said it delivered 25 percent more DecisionDx-Melanoma test results year over year, and that the total number of all tests delivered rose 62 percent.
The acquisition of Cernostics and its TissueCypher Barrett's Esophagus Assay provides a route for Castle to enter gastrointestinal testing.
Castle Biosciences Acquires Cernostics for up to $80M
Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies.
Aug 9, 2021
Castle Biosciences Q2 Revenues Rise 79 Percent
May 11, 2021
May 10, 2021
Castle Biosciences Q1 Revenues Up 31 Percent
Mar 8, 2021
Castle Biosciences Q4 Revenues Down 2 Percent
Nov 9, 2020
Castle Biosciences Q3 Revenues Up 3 Percent
Aug 10, 2020